DNA methylation in ductal carcinoma in situ of the breast

Breast Cancer Research

Volumn 15, Issue 3, 2013, Pages

  Pang, Jia Min B ^a,b   Dobrovic, Alexander ^a,b   Fox, Stephen B ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CPG OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2; CYTOSINE; DNA; DNA METHYLTRANSFERASE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BNIP3; PROTEIN P16; PROTEIN P21; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR FOXC1; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIMIT OF DETECTION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROMOTER REGION; REVIEW; RISK FACTOR; TUMOR VOLUME; BREAST TUMOR; CARCINOGENESIS; FEMALE; GENETIC EPIGENESIS; GENETICS; PATHOLOGY;

BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; PROMOTER REGIONS, GENETIC;

EID: 84879800299     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3420     Document Type: Review

References (101)

1. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010, 102:170-178. 10.1093/jnci/djp482, 20071685.
2. , Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: tenyear results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24:3381-3387. 10.1200/JCO.2006.06.1366, 16801628, EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group.
3. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000. 10.1016/S0140-6736(99)05036-9, 10376613.
4. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95-102. 10.1016/S0140-6736(03)13859-7, 12867108.
5. Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, Naehrig D, Miller RC, Krengli M, Gutierrez Miguelez C, Morgan D, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Gruber G. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006, 7:652-656. 10.1016/S1470-2045(06)70765-3, 16887482.
6. Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. J Natl Cancer Inst Monogr 2010, 2010:181-186. 10.1093/jncimonographs/lgq041, 20956826.
7. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011, 12:21-29. 10.1016/S1470-2045(10)70266-7, 3018565, 21145284.
8. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 2012, 10:CD007847.
9. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001, 344:1997-2008. 10.1056/NEJM200106283442607, 11430330.
10. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC. Local excision alone without irradiation for ductal carcinoma in situof the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:5319-5324. 10.1200/JCO.2009.21.8560, 2773217, 19826126.
11. Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 2011, 127:1-14. 10.1007/s10549-011-1387-4, 21327465.
12. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011, 2:232-261. 3088863, 21552384.
13. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L. HER2/neu and Ki-67 expression predict noninvasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012, 106:1160-1165. 10.1038/bjc.2012.41, 3304413, 22361634.
14. Holmes P, Lloyd J, Chervoneva I, Pequinot E, Cornfield DB, Schwartz GF, Allen KG, Palazzo JP. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer 2011, 117:3650-3657. 10.1002/cncr.25942, 21319154.
15. Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, Fentiman IS, George WD. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 2010, 103:94-100. 10.1038/sj.bjc.6605718, 2905282, 20517310.
16. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009, 27:1615-1620. 10.1200/JCO.2008.17.5182, 19255332.
17. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003, 39:622-630. 10.1016/S0959-8049(02)00666-4, 12628841.
18. de Roos MA, de Bock GH, de Vries J, van der Vegt B, Wesseling J. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 2007, 140:109-114. 10.1016/j.jss.2006.10.045, 17291532.
19. Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W. Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol 2008, 2:7-18. 3161685, 21892261.
20. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, Rabban J, Chen YY, Kerlikowske K, Tlsty TD. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007, 12:479-491. 10.1016/j.ccr.2007.10.017, 3605202, 17996651.
21. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010, 102:627-637. 10.1093/jnci/djq101, 2864293, 20427430.
22. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol 2011, 179:1171-1178. 10.1016/j.ajpath.2011.05.043, 3157259, 21756866.
23. Hieken TJ, Cheregi J, Farolan M, Kim J, Velasco JM. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. Am J Surg 2007, 194:504-506. 10.1016/j.amjsurg.2007.07.002, 17826066.
24. Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 2007, 13:467-474. 10.1158/1078-0432.CCR-06-1466, 17255267.
25. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003, 100:5974-5979. 10.1073/pnas.0931261100, 156311, 12714683.
26. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003, 1:362-375.
27. Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL, Meltzer PS. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 2008, 14:8244-8252. 10.1158/1078-0432.CCR-08-0939, 19088042.
28. Lambert K, Patani N, Mokbel K. Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol 2012, 2012:347385. 3362914, 22675624.
29. Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 2012, 12:473-487. 10.1586/erm.12.45, 22702364.
30. Mikeska T, Candiloro IL, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics 2010, 2:561-573. 10.2217/epi.10.32, 22121974.
31. Harrison A, Parle-McDermott A. DNA methylation: a timeline of methods and applications. Front Genet 2011, 2:74. 3268627, 22303369.
32. Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 2009, 55:1471-1483. 10.1373/clinchem.2008.121962, 19520761.
33. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001, 61:2782-2787.
34. Kang JH, Kim SJ, Noh DY, Park IA, Choe KJ, Yoo OJ, Kang HS. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 2001, 81:573-579. 10.1038/labinvest.3780266, 11304577.
35. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001, 20:3348-3353. 10.1038/sj.onc.1204438, 11423985.
36. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002, 160:605-612. 10.1016/S0002-9440(10)64880-8, 1850646, 11839581.
37. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003, 107:970-975. 10.1002/ijc.11508, 14601057.
38. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER, Latif F. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003, 22:147-150. 10.1038/sj.onc.1206057, 12527916.
39. Yuan Y, Liu H, Sahin A, Dai JL. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 2005, 113:654-659. 10.1002/ijc.20628, 15455373.
40. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 2004, 64:1611-1620. 10.1158/0008-5472.CAN-0318-2, 14996719.
41. Futscher BW, O'Meara MM, Kim CJ, Rennels MA, Lu D, Gruman LM, Seftor RE, Hendrix MJ, Domann FE. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 2004, 6:380-389. 10.1593/neo.04115, 1502109, 15256060.
42. Lo PK, Mehrotra J, D'Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S. Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther 2006, 5:281-286. 10.4161/cbt.5.3.2384, 16410723.
43. Liu T, Niu Y, Feng Y, Niu R, Yu Y, Lv A, Yang Y. Methylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast. Hum Pathol 2008, 39:1637-1646. 10.1016/j.humpath.2008.04.001, 18657295.
44. Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Argani P, Sukumar S. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis. Cancer Biol Ther 2008, 7:1398-1406.
45. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2009, 113:113-121. 10.1007/s10549-008-9917-4, 18256927.
46. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, Gallo AP, Brait M, Maiello E, Apicella A, Rossiello R, Zito F, Stefania T, Paradiso A, Carella M, Dallapiccola B, Murgo R, Carosi I, Bisceglia M, Fazio VM, Sidransky D, Parrella P. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009, 18:2694-2700. 10.1158/1055-9965.EPI-08-0821, 19789364.
47. Muggerud AA, Rønneberg JA, Wärnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Børresen-Dale AL, Kristensen VN, Sørlie T, Tost J. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 2010, 12:R3. 10.1186/bcr2466, 2880421, 20056007.
48. Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011, 225:222-231. 10.1002/path.2930, 21710692.
49. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011, 458:73-84. 10.1007/s00428-010-1013-6, 21120523.
50. Iakovlev VV, Arneson NC, Wong V, Wang C, Leung S, Iakovleva G, Warren K, Pintilie M, Done SJ. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res 2008, 14:4446-4454. 10.1158/1078-0432.CCR-07-4960, 18628458.
51. Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, Lidereau R. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002, 196:280-286. 10.1002/path.1048, 11857490.
52. Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA 2001, 98:9796-9801. 10.1073/pnas.171138398, 55532, 11481438.
53. Verschuur-Maes AH, de Bruin PC, van Diest PJ. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Res Treat 2012, 136:705-715. 10.1007/s10549-012-2301-4, 23104224.
54. Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S, Rom J, Weichenhan D, Claus R, Rehli M, Schirmacher P, Sinn HP, Plass C, Gerhauser C. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 2012, 26:4937-4950. 10.1096/fj.12-209502, 22930747.
55. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 2009, 11:R14. 10.1186/bcr2233, 2687719, 19250546.
56. Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch 2007, 450:637-642. 10.1007/s00428-007-0421-8, 17479284.
57. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004, 64:3871-3877. 10.1158/0008-5472.CAN-03-3690, 15172996.
58. Xu X, Gammon MD, Zhang Y, Cho YH, Wetmur JG, Bradshaw PT, Garbowski G, Hibshoosh H, Teitelbaum SL, Neugut AI, Santella RM, Chen J. Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2010, 121:685-692. 10.1007/s10549-009-0628-2, 2869387, 19921426.
59. Jiang Y, Cui L, Chen WD, Shen SH, Ding LD. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One 2012, 7:e36780. 10.1371/journal.pone.0036780, 3355150, 22615811.
60. Dejeux E, Rønneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Børresen-Dale AL, Lønning PE, Kristensen VN, Tost J. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 2010, 9:68. 10.1186/1476-4598-9-68, 2861056, 20338046.
61. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, Xu X, Bradshaw PT, Teitelbaum SL, Garbowski G, Hibshoosh H, Neugut AI, Chen J, Santella RM. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat 2012, 131:197-205. 10.1007/s10549-011-1712-y, 3576848, 21837480.
62. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 2011, 71:2988-2999. 10.1158/0008-5472.CAN-10-4026, 21363912.
63. Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N, European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 2007, 43:1679-1686. 10.1016/j.ejca.2007.04.025, 17601725, European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
64. Swift-Scanlan T, Vang R, Blackford A, Fackler MJ, Sukumar S. Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther 2011, 11:853-865. 10.4161/cbt.11.10.15177, 3116929, 21383541.
65. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012, 107:75-83. 10.1038/bjc.2012.212, 3389412, 22653144.
66. Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T. Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPdelta) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer 2012, 107:732-738. 10.1038/bjc.2012.308, 22782348.
67. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64:3807-3813. 10.1158/0008-5472.CAN-03-3852, 15172987.
68. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005, 65:4101-4117. 10.1158/0008-5472.CAN-05-0064, 15899800.
69. Hurd PJ, Nelson CJ. Advantages of next-generation sequencing versus the microarray in epigenetic research. Brief Funct Genomic Proteomic 2009, 8:174-183. 10.1093/bfgp/elp013, 19535508.
70. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010, 11:191-203.
71. Zhao Q, Zhang Y. Epigenome sequencing comes of age in development, differentiation and disease mechanism research. Epigenomics 2011, 3:207-220. 10.2217/epi.10.78, 22122282.
72. Ku CS, Naidoo N, Wu M, Soong R. Studying the epigenome using next generation sequencing. J Med Genet 2011, 48:721-730. 10.1136/jmedgenet-2011-100242, 21825079.
73. Hirst M, Marra MA. Next generation sequencing based approaches to epigenomics. Brief Funct Genomics 2010, 9:455-465. 10.1093/bfgp/elq035, 3080743, 21266347.
74. Carvalho RH, Haberle V, Hou J, van Gent T, Thongjuea S, van Ijcken W, Kockx C, Brouwer R, Rijkers E, Sieuwerts A, Foekens J, van Vroonhoven M, Aerts J, Grosveld F, Lenhard B, Philipsen S. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin 2012, 5:9. 10.1186/1756-8935-5-9, 3407794, 22726460.
75. Gu H, Bock C, Mikkelsen TS, Jager N, Smith ZD, Tomazou E, Gnirke A, Lander ES, Meissner A. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat Methods 2010, 7:133-136. 10.1038/nmeth.1414, 2860480, 20062050.
76. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, Huang C, Shankar S, Jing X, Iyer M, Hu M, Sam L, Grasso C, Maher CA, Palanisamy N, Mehra R, Kominsky HD, Siddiqui J, Yu J, Qin ZS, Chinnaiyan AM. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011, 21:1028-1041. 10.1101/gr.119347.110, 3129246, 21724842.
77. Weng YI, Huang TH, Yan PS. Methylated DNA immunoprecipitation and microarray-based analysis: detection of DNA methylation in breast cancer cell lines. Methods Mol Biol 2009, 590:165-176. 10.1007/978-1-60327-378-7_10, 2845920, 19763503.
78. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 2010, 11:137. 10.1186/1471-2164-11-137, 2838848, 20181289.
79. Morita S, Takahashi RU, Yamashita R, Toyoda A, Horii T, Kimura M, Fujiyama A, Nakai K, Tajima S, Matoba R, Ochiya T, Hatada I. Genome-wide analysis of DNA methylation and expression of microRNAs in breast cancer cells. Int J Mol Sci 2012, 13:8259-8272. 10.3390/ijms13078259, 3430232, 22942701.
80. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992, 89:1827-1831. 10.1073/pnas.89.5.1827, 48546, 1542678.
81. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994, 22:2990-2997. 10.1093/nar/22.15.2990, 310266, 8065911.
82. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35:146-150.
83. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003, 35:152-156.
84. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005, 102:15785-15790. 10.1073/pnas.0507816102, 1276092, 16243968.
85. Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ. Genomic profiling of CpG methylation and allelic specificity using quantitative highthroughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 2007, 35:e119. 10.1093/nar/gkm662, 2094090, 17855397.
86. Herman JG, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
87. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28:E32. 10.1093/nar/28.8.e32, 102836, 10734209.
88. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 2008, 36:e42. 10.1093/nar/gkn113, 2367707, 18344521.
89. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007, 35:e41. 10.1093/nar/gkm013, 1874596, 17289753.
90. Bianco T, Hussey D, Dobrovic A. Methylation-sensitive, single-strand conformation analysis (MS-SSCA): a rapid method to screen for and analyze methylation. Hum Mutat 1999, 14:289-293. 10.1002/(SICI)1098-1004(199910)14:4<289::AID-HUMU3>3.0.CO;2-A, 10502775.
91. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res 1997, 25:2529-2531. 10.1093/nar/25.12.2529, 146734, 9171109.
92. Gonzalgo ML, Jones PA. Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods 2002, 27:128-133. 10.1016/S1046-2023(02)00064-6, 12095270.
93. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997, 25:2532-2534. 10.1093/nar/25.12.2532, 146738, 9171110.
94. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005, 33:e128. 10.1093/nar/gni127, 1187824, 16106041.
95. Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. Epigenetics Chromatin 2008, 1:7. 10.1186/1756-8935-1-7, 2590600, 19014416.
96. Candiloro IL, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila) 2009, 2:862-867. 10.1158/1940-6207.CAPR-09-0056, 19789298.
97. Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K, Schmidt K, He Y, Diehl F, Velculescu VE, Zhou S, Diaz LA, Kinzler KW, Markowitz SD, Vogelstein B. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009, 27:858-863. 10.1038/nbt.1559, 2847606, 19684580.
98. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000, 275:2727-2732. 10.1074/jbc.275.4.2727, 10644736.
99. Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003, 16:1095-1101. 10.1097/01.MP.0000095782.79895.E2, 14614048.
100. Pasquali L, Bedeir A, Ringquist S, Styche A, Bhargava R, Trucco G. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett 2007, 257:136-144. 10.1016/j.canlet.2007.07.010, 17706863.
101. Alvarez C, Tapia T, Cornejo V, Fernandez W, Munoz A, Camus M, Alvarez M, Devoto L, Carvallo P. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. Mol Carcinog 2013, 52:475-487. 10.1002/mc.21881, 22315090.